PAPER Jongbloed W, Herrebout MA, Blankenstein MA, Veerhuis R
SEARCH RESULTS
331209 RESULTS
PAPER Helal M, Hingant E, Pujo-Menjouet L, Webb GF
Alzheimer's disease: analysis of a mathematical model incorporating the role of prions.
J Math Biol. 2013 Oct 22; PubMed: 24146290PAPER Adewusi EA, Fouche G, Steenkamp V
Effect of Four Medicinal Plants on Amyloid-β Induced Neurotoxicity in SH-SY5Y Cells.
Afr J Tradit Complement Altern Med. 2013;10(4):6-11. PubMed: 24146494PAPER Leugers CJ, Koh JY, Hong W, Lee G
Tau in MAPK activation.
Front Neurol. 2013;4:161. PubMed: 24146661PAPER Devi L, Ohno M
Deletion of the eIF2α Kinase GCN2 Fails to Rescue the Memory Decline Associated with Alzheimer's Disease.
PLoS One. 2013;8(10):e77335. PubMed: 24146979PAPER Tola-Arribas MA, Yugueros MI, Garea MJ, Ortega-Valín F, Cerón-Fernández A, Fernández-Malvido B, San José-Gallegos A, González-Touya M, Botrán-Velicia A, Iglesias-Rodríguez V, Díaz-Gómez B
Prevalence of Dementia and Subtypes in Valladolid, Northwestern Spain: The DEMINVALL Study.
PLoS One. 2013;8(10):e77688. PubMed: 24147055PAPER Theendakara V, Patent A, Peters Libeu CA, Philpot B, Flores S, Descamps O, Poksay KS, Zhang Q, Cailing G, Hart M, John V, Rao RV, Bredesen DE
Neuroprotective Sirtuin ratio reversed by ApoE4.
Proc Natl Acad Sci U S A. 2013 Nov 5;110(45):18303-8. PubMed: 24145446Giulio Pasinetti on Low Dose Bexarotene Treatment Rescues Dopamine Neurons and Restores Behavioral Function in Models of Parkinson's Disease.
COMMENT This is a very exciting paper discussing the role of Rexinoid X Receptor (RXR) agonists in the treatment of Parkinson’s disease. Overall, at least from a conceptual point of view, McFarland et al. provide confirmatory evidence for the mechanistic role of
Clinical Trials on Alzheimer’s Disease 2009
CONFERENCE 2009-10-29 00:00:00-2009-10-30 00:00:00 Las Vegas, NV, U.S.A. 29 October 2009 to 30 October 2009 The aims of the meeting are to bring together the current leaders in clinical trials in Alzheimer’s Disease to discuss new results, drugs in development, and future methodological issues (disease mo
MAPT N255N
MUTATIONS MAPT 44073973 GRCh37/hg19 rs17652121 T C g.110013T> C g.107187T> C Exon 9 Point, Silent Coding Unknown. Not applicable. N255N Frontotemporal Dementia: BenignNone This variant in exon 9 is a relatively common polymorphism and is not associated with p
Sanjay Pimplikar on Amyloid-β oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin.
COMMENT This study by Zempel et al. reveals a potential mechanism by which Aβ oligomers exert tau-mediated toxic effects on microtubules. In this study, Aβ oligomers (ADDLs) were prepared from a mixture of Aβ1-40 and Aβ1-42 at a ratio of 7:3 and were used at 1 µM
International Conference on Frontotemporal Dementias 2014
CONFERENCE 2014-10-23 00:00:00-2014-10-25 00:00:00 Vancouver, British Columbia, Canada 23 October 2014 to 25 October 2014 Vancouver was recently selected to host the 9th International Conference on Frontotemporal Dementias (ICFTD), which will take place at the Sheraton Vancouver Wall Centre, from October
Renuka Ranjan
Banaras Hindu UniversityBallia, India
Formal Guidelines Issued for Alzheimer’s Genetic Testing
Other 15 July 2011. Communicating genetic information about Alzheimer’s disease to patients and families can be a daunting challenge. Clinicians and researchers faced with this task can take heart, however, because comprehensive guidelines for AD genetic testin
Protocol for Predictive Testing
Other Introduction by Gabrielle Strobel This is a simplified version of the protocol for predictive testing as used at the Alzheimer Disease Research Center at Columbia University, New York. It is based on the protocol for Huntington disease developed at the Co
Current Filters
No filters selected